SPAF
1991
Stroke Prevention in Atrial Fibrillation Study
In 1,330 patients with non-rheumatic atrial fibrillation, warfarin and aspirin each reduced ischaemic stroke or systemic embolism compared with placebo.
Result
Primary endpoint: Ischaemic stroke or systemic embolism
Aspirin 3.6%/yr vs placebo 6.3%/yr (42% risk reduction, 95% CI 9-63%; P=0.02). Warfarin reduced events by 67% vs placebo (95% CI 27-85%; P=0.01). Both positive.
- Subtopic
- antithrombotic
- Design
- Multicentre RCT (warfarin/aspirin vs placebo)
- Relevance
- Supporting: context rather than must-know.
- Cited in
- ESC 2024 AFACC/AHA 2023 AF
- Source
- Stroke Prevention in Atrial Fibrillation Investigators. Circulation. 1991;84(2):527-539.doi 10.1161/01.CIR.84.2.527
Discussion & critique
Short follow-up and stratified design without head-to-head warfarin-versus-aspirin randomisation across all patients. Landmark evidence establishing antithrombotic therapy for stroke prevention in atrial fibrillation.